Willebrand

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024
Fabry disease, RMB, PD, Drug development, Strong, Ohio State University, RNA, Insight Partners, Pharmacology, American College, Radiopharmaceutical, VBI, Willebrand, RTW, Pattern hair loss, GMP, Stroke, Good manufacturing practice, Therapy, Skin, GCS, Atopic dermatitis, Safety, Pharmacokinetics, Von Willebrand factor, Investment, AstraZeneca, Innovation, Groundbreaking, Patient, ARCH Venture Partners, Pharmaceutical industry

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

Retrieved on: 
Thursday, February 1, 2024
Cardiology, Biotechnology, Managed Care, Other Health, Health, Pharmaceutical, Other Science, Research, Hospitals, Science, Clinical Trials, Willebrand, RTW, ARCH Venture Partners, RNA, Joseph, Thrombosis, University, Translational research, Patient, Safety, Foothills Medical Centre, AIS, Insight Partners, Ohio State University, Investment, Radiology, Stroke, Surgery, Medicine, Von Willebrand factor, Pharmaceutical industry

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.

Key Points: 
  • Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.
  • Steven Gillis, Ph.D., Managing Director of ARCH Venture Partners will serve as Chairman of Basking’s Board of Directors .
  • Basking will utilize the proceeds to accelerate clinical development of BB-031, a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), engineered for rapid onset and short duration of effect.
  • Basking will initiate a Phase 2 proof-of-concept trial, the RAISE trial, in patients with acute ischemic stroke (AIS) in 2024.

Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference

Retrieved on: 
Tuesday, May 9, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Partnership, University of Massachusetts, Bleeding, Stroke, Toxicity, Brain, RNA, Willebrand, Von Willebrand factor, Blood, MRI, Patient, Thrombus, Beth Israel, Aptamer, Conference, Vaccine

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.

Key Points: 
  • Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.
  • BB-031, a rapid onset, short-acting agent, is an RNA aptamer targeting von Willebrand Factor (vWF), a key structural component of thrombi and driver of blood clotting.
  • Uniquely, the thrombolytic activity of BB-031 is designed to be quickly neutralized in the event of bleeding using a complementary agent, BB-025, which Basking is developing in tandem.
  • “RNA aptamers have a number of characteristics that make them exceptionally well suited for treating acute thrombosis,” said Richard Shea, Chief Executive Officer of Basking.

Von Willebrand Disease Market Market Forecast Across G5 Countries to 2030 with Key Focus on Vonvendi (Takeda) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Other Health, Countries, Western Asia, Willebrand, Asia, Von Willebrand disease, Saudi Arabia

What was the Von Willebrand Disease market share (%) distribution in 2017 and how it would look like in 2030?

Key Points: 
  • What was the Von Willebrand Disease market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Von Willebrand disease market growth till 2030, and what will be the resultant market Size in the year 2030?
  • What is the historical Von Willebrand disease patient pool in G5 countries markets covering Algeria, Egypt, Saudi Arabia, South Africa and the United Arab Emirates?
  • Out of all G5 countries, which country would have the highest prevalent population of Von Willebrand disease during the forecast period (2017-2030)?

Von Willebrand Disease Epidemiology Forecast 2021-2030 - Focus on Algeria, Egypt, Saudi Arabia, South Africa and United Arab Emirates - ResearchAndMarkets.com

Retrieved on: 
Friday, February 19, 2021
Health, Other Health, Countries, Western Asia, Regions, Willebrand, Von Willebrand disease, Saudi Arabia, G5

This 'Von Willebrand disease - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Von Willebrand disease epidemiology in the G5, i.e., Algeria, Egypt, Saudi Arabia, South Africa and United Arab Emirates.

Key Points: 
  • This 'Von Willebrand disease - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Von Willebrand disease epidemiology in the G5, i.e., Algeria, Egypt, Saudi Arabia, South Africa and United Arab Emirates.
  • The Von Willebrand disease epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in G5.
  • The Von Willebrand disease epidemiology covered in the report provides historical as well as forecasted Von Willebrand disease epidemiology scenario in the G5 covering Algeria, Egypt, Saudi Arabia, South Africa and the United Arab Emirates from 2017 to 2030.
  • The Von Willebrand disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Von Willebrand disease report and model provide an overview of the global trends of Von Willebrand disease in the G5 countries (G5: Algeria, Egypt, Saudi Arabia, South Africa and the United Arab Emirates).

Europe Von Willebrand Disease Market and Competitive 2020: Pipeline, Epidemiology, Market Valuations, Treatment Options, Drug Sales, Market Forecast, Drug Forecasts, and Market Shares 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020
Health, General Health, Willebrand, Von Willebrand disease, Clinical medicine, Branches of biology, Medicine

Europe Von Willebrand Disease Market and Competitive Landscape - 2020, provides comprehensive insights into the Von Willebrand Disease pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • Europe Von Willebrand Disease Market and Competitive Landscape - 2020, provides comprehensive insights into the Von Willebrand Disease pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Von Willebrand Disease market size and drug sales.
  • This research covers the following:
    Von Willebrand Disease treatment options, Von Willebrand Disease late stage clinical trials pipeline, Von Willebrand Disease prevalence by countries, Von Willebrand Disease market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Von Willebrand Disease pipeline: Find out drugs in clinical trials for the treatment of Von Willebrand Disease by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Von Willebrand Disease drugs: Identify key drugs marketed and prescribed for Von Willebrand Disease in the US, including trade name, molecule name, and company
    Von Willebrand Disease drugs sales: Find out the sales value for Von Willebrand Disease drugs by countries
    Von Willebrand Disease market valuations: Find out the market size for Von Willebrand Disease drugs in 2019 by countries.

Analysis on Impact of COVID-19- Global Von Willebrand Disease Therapeutics Market 2020-2024 | Evolving Opportunities with Apotex Inc. and Baxter International Inc. | Technavio

Retrieved on: 
Monday, September 7, 2020
Health, Other Health, Drugs, Von Willebrand disease, Clinical medicine, Health, Willebrand, Desmopressin, Apotex, Vonicog alfa

The global von willebrand disease (VWD) therapeutics market size is expected to grow by USD 165.48 million as per Technavio.

Key Points: 
  • The global von willebrand disease (VWD) therapeutics market size is expected to grow by USD 165.48 million as per Technavio.
  • In addition, the special regulatory designations are anticipated to boost the growth of the Von Willebrand Disease Therapeutics Market.
  • Major Five Von Willebrand Disease Therapeutics Companies:
    Apotex Inc. offers more than 300 generic pharmaceuticals in approximately 4000 dosages.
  • The company offers Desmopressin which is used for the treatment of patients with mild to moderate classic Von Willebrand disease.

The Global Von Willebrand Disease Therapeutics Market is expected to grow by $ 165.48 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period

Retrieved on: 
Tuesday, September 1, 2020
Willebrand, Von Willebrand disease, Clinical medicine, Medicine, Medical specialties

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- The analyst has been monitoring the Von Willebrand Disease Therapeutics market and it is poised to grow by $ 165.48 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period.

Key Points: 
  • NEW YORK, Sept. 1, 2020 /PRNewswire/ -- The analyst has been monitoring the Von Willebrand Disease Therapeutics market and it is poised to grow by $ 165.48 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period.
  • Our reports on Von Willebrand Disease Therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The Von Willebrand Disease Therapeutics market analysis includes product segment and geographic landscapes.
  • The Von Willebrand Disease Therapeutics market is segmented as below:

National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease

Retrieved on: 
Monday, August 10, 2020
Entertainment, Health, Celebrity, Genetics, Managed care, General Health, Pharmaceutical, Blood, Clinical medicine, Medical specialties, Von Willebrand disease, Haemophilia, Erik Adolf von Willebrand, Coagulopathy, Bleeding, Willebrand, von Willebrand disease (VWD), National Hemophilia Foundation, Takeda Hematology, Takeda Pharmaceutical Company

Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.

Key Points: 
  • Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.
  • "Taking an active role in the bleeding disorder community isn't a choice for me; it's a responsibility," said Borstein.
  • "Von Willebrand disease affects millions of Americans but is often overlooked, even by some healthcare professionals.
  • Takeda is proud to partner with NHF to help raise awareness around VWD.

Von Willebrand Disease - Global Market Valuations, Pipeline, Epidemiology, Drugs, Sales, Shares and Forecasts to 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 17, 2020
Health, General Health, Willebrand, Von Willebrand disease, Medicine, Medical specialties, Clinical medicine

This research report provides comprehensive insights into the Von Willebrand Disease pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This research report provides comprehensive insights into the Von Willebrand Disease pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Von Willebrand Disease market size and drug sales.
  • The report covers the following: Von Willebrand Disease treatment options, Von Willebrand Disease late stage clinical trials pipeline, Von Willebrand Disease prevalence by countries, Von Willebrand Disease market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Von Willebrand Disease pipeline: Find out drugs in clinical trials for the treatment of Von Willebrand Disease by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Von Willebrand Disease drugs: Identify key drugs marketed and prescribed for Von Willebrand Disease in the US, including trade name, molecule name, and company
    Von Willebrand Disease drugs sales: Find out the sales value for Von Willebrand Disease drugs by countries
    Von Willebrand Disease market valuations: Find out the market size for Von Willebrand Disease drugs in 2019 by countries.